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 21 
ABSTRACT 22 
Background: Maternal high-fat (HF) and cholesterol-rich diets increase cardiovascular disease risk in 23 
mothers and offsprings, and treatment with statins reduce this risk.  24 
Objectives: We hypothesize that one possible statin-related protective mechanism in pregnant mothers 25 
and offsprings fed on HF diet is the reduction in impairment of the vasculogenic element of endothelial 26 
regeneration.  27 
Methods: To explore this, virgin C57BL/6 mice (n = 8/group) were fed HF diet (fat- 45% kcal) or 28 
standard chow (C; fat- 21% kcal) from weaning and throughout their pregnancy and lactation. Half of 29 
the HF group was also given the HMG-Co-A reductase inhibitor pravastatin (S) through their drinking 30 
water (5 mg/kg body weight per day) to create HF+S dam group. Offspring from each group were fed 31 
HF or C diets from weaning to adulthood, generating respective dam/offspring dietary groups (C/C, 32 
HF/HF, HF+S/HF). Body weight, blood pressure and serum lipid profile were measured in offspring at 33 
24 weeks of age, and bone marrow endothelial progenitor cells (EPCs) were cultured.  34 
Results: The results indicate that in the female offsprings, the statin-fed (HF+S/HF) cohort had lower 35 
total and low-density lipoprotein cholesterol concentrations, were less obese and hypertensive and 36 
showed increased bone marrow EPCs expressing colony numbers (P < 0.001) as compared with the 37 
HF/HF phenotype.  38 
Conclusions:  Our results demonstrate that statin administration in early life to dams fed a HF diet had 39 
a significant impact on their female offspring in terms of reduction in cardiovascular risk factors. In 40 
addition, statin administration to female offsprings on HF diet during early life was associated with 41 
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reduction in circulating C-reactive proteins (CRPs) and an increased bone marrow EPC numbers and 42 
colony-forming characteristics. 43 
 44 
KEYWORDS: blood pressure, cardiovascular dysfunction, developmental programming, HMG-CoA 45 
reductase inhibition, endothelial progenitor cells, C-reactive proteins 46 
 47 
INTRODUCTION 48 
Endothelial dysfunction is a common phenomenon that occurs in the metabolic syndrome (1, 2). 49 
Evidence suggests that diabetes and hyperlipidemia leads to reduced circulation of blood and bone 50 
marrow-derived mononuclear cells, i.e. endothelial progenitor cells (EPCs), thus resulting in 51 
endothelial cell dysfunction (3-6). Emerging reports also suggest endothelial dysfunction (i.e. reduced 52 
EPC) as a common phenotype in a number of rodent models of both maternal HF and total nutrient 53 
restriction in the context of developmental origins of health and disease (DOHaD) models (7, 8). 54 
 55 
In response to marked morphological changes in the surrounding mature endothelial cells, EPCs play a 56 
critical role in maintaining endothelial function in mature blood vessels by contributing to re-57 
endothelialisation and neovascularisation (9, 10). It is therefore conceivable that the mobilization and 58 
differentiation of EPCs are important in this process of adult neovascularization (11-13) and any 59 
impairment of this vasculogenic element of endothelial regeneration may account for the progression of 60 
endothelial dysfunction (13). 61 
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Accumulating evidence also suggests that the number and migratory activity of circulating EPCs 62 
inversely correlate with circulating C-reactive protein (CRP) levels (4, 14). The combination of 63 
reduced circulating EPCs and increased circulating CRP is known to be associated with metabolic 64 
syndrome and high LDL cholesterol (15, 16). Reports have advocated that CRP down-regulates 65 
endothelial nitric oxide synthase (eNOS) in a synchronous fashion and destabilizes eNOS mRNA 66 
transcription, decreases both basal and stimulated nitric oxide (NO) release (17), up-regulates nuclear 67 
factor kappa-B (NF-κB), a key nuclear factor that facilitates the transcription of numerous pro-68 
atherosclerotic genes) (18), and mediates adhesion molecules and LDL uptake (19, 20). 69 
These interrelations among LDL cholesterol, CRP and bone marrow EPC, suggest that CRP-related 70 
alteration in progenitor cell number and function in offspring may be induced by maternal HF 71 
consumption. Also it would be interesting to study, through net reduction effect on maternal 72 
dyslipidemia load, whether statin therapy in dams exerts any advantageous effect on bone marrow EPC 73 
in their offspring fed a similar high-fat diet. These hypotheses are supported by several experimental 74 
models and in vivo studies on ischemic disease patients (21, 22). Although, the precise mechanisms 75 
remain unclear, it is known that statin improves endothelial function by activating protein kinase Akt 76 
(21), mobilizing EPC (23), reducing senescence, and increasing proliferation of EPC (24). 77 
A major area of DOHaD research provides a novel explanation on disturbances in the maternal 78 
metabolism resulting from altered nutrient supply in the mother, a trait that is transmitted to the fetus in 79 
the form of structural and functional adaptations during fetal development and throughout life (25-28). 80 
Consequently, we developed a mice model (29, 30) for studying the effect of altered maternal nutrients 81 
supply in the mother transmitted to the fetus during development. In these studies (29, 30) we reported 82 
that statin administration during the second half of pregnancy and lactation in dams consuming a HF 83 
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diet reduces metabolic risk factors not only in dams but also in their offspring (31). These favorable 84 
effects were more prominent in the offspring of HF mothers who had statin treatment at the time they 85 
were weaned, during pregnancy and lactation (31). However, it is not clear what the possible 86 
underlying mechanism is. We hypothesize that one such possible protective mechanism in pregnant 87 
mothers and offsprings fed on HF diet is the reduction in impairment of the vasculogenic element of 88 
endothelial regeneration. We believe that statins reduce the levels of circulating CRPs that may be 89 
linked with the pathological mechanisms that regulate bone marrow EPC numbers and their colony-90 
forming properties. Our study was designed to compare the effect of statin with that of other 91 
hypercholesterolemic drugs and to use an experimental design that minimizes the differences in body 92 
weight and other parameters induced by a high-fat diet before pregnancy as well as during lactation as 93 
described in more detail in our previous publications (29-31). In brief, using this model we had 94 
previously explored the impact of long-term consumption of a high-fat diet by pregnant mothers. The 95 
results indicated that high-fat diet in pregnant mothers predisposes her female offspring to developing a 96 
metabolic syndrome-like phenotype in adult life as indicated by chronic elevation of serum cholesterol 97 
and blood pressure. In the follow-on study (30) using the same model, we observed that offsprings 98 
from high-fat fed dams showed increased adiposity in their femurs in comparison to offsprings from 99 
mothers fed standard chow. In particular, female offsprings from mothers fed a high-fat diet exhibited 100 
altered trabecular structure, indicative of in utero programming. However, the scope covered by all our 101 
studies was limited by the availability of funding and other resources, and hence the focus of this study 102 
was on metabolic syndrome-like outcomes. However, the use of this type of model to test the effect of 103 
treatment with statins does not find direct relevance to clinical practice in view of the existing 104 
controversy concerning the potential high risk of teratogenicity to the unborn fetus (32). 105 
 106 
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MATERIALS AND METHODS 107 
 108 
Experimental Protocol 109 
Study part I 110 
The aim of this protocol is to resolve the question whether statins when administered to pregnant 111 
mothers on a high-fat diet has any effect on the mechanisms of endothelial regeneration. All of the 112 
animal procedures were humane and carried out in accordance with the United Kingdom Animals 113 
(Scientific Procedures) Act 1986 and the study protocol was approved by the University of 114 
Southampton Animal Care and Research Ethics Committee. The experimental protocol for study-I is as 115 
described on figure 1. Female C57BL/6 mice (Charles River Laboratories, United Kingdom) were 116 
maintained under a 12-hour light-dark cycle at constant temperature (25 + 2 °C) with food and water 117 
supplied ad libitum. At 4 weeks of age, the females were randomly allocated to either a control diet of 118 
standard laboratory chow (C; 5.3% fat [corn oil], 21.2% protein, 49.2% carbohydrate; Special Diet 119 
Services, United Kingdom) or an HF experimental diet (29-31) 2 supplemented with 18% 120 
weight/weight animal lard, with additional vitamins and minerals, protein, and choline to correct for the 121 
dilution (final composition in percentage of grams [weight/weight]: lard 17.8; casein 26.5; choline 122 
chloride 0.3; L-cysteine 0.4; rice starch 28.3; cellulose 6.1; soya oil 4.3; sucrose 10.4; minerals 4.3 and 123 
vitamins 1.2; Special Diet Services diet 824053). This HF diet has been used in previous studies (33, 124 
34). At 10 weeks old, the females were time mated and after confirmation of mating (i.e. presence of 125 
vaginal plug), were individually housed. From the second half of the pregnancy and throughout 126 
lactation, half of the pregnant females on the HF diet were given a water-soluble 3-hydroxy3-127 
                                                          
2
 The composition of the diets has been published in the following citations: 
29. Elahi MM et al., Hypertension 2008; 51 (4): 939-44  
30. Elahi MM et al., Br J Nutr 2009; 102 (4): 514-9 
31. Elahi MM et al., Ann Nutr Metab 2013; 62 (3): 250-6 
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methylglutaryl-coenzyme A reductase inhibitor (pravastatin, Sigma United Kingdom) in their drinking 128 
water (HF+S). Pravastatin was dissolved at a concentration that gave a daily dose of 5 mg/kg per day, 129 
based on the daily water consumption of pregnant and lactating mice predetermined from our previous 130 
study (33). The pregnant dams were allowed to give birth, and the pups were weighed, and litter size 131 
was standardized to 8 pups. After weaning (3 weeks postpartum), all female offsprings whose mothers 132 
had been fed on diets of C, HF and HF+S, were themselves randomly allocated to be fed on either C, or 133 
HF. This generated mother and daughter dietary combinations of C/C, C/HF, HF/HF, HF/C; HF+S/HF 134 
and HF+S/C. The female offsprings were monitored until 24 weeks of age in terms of body weights 135 
(from 1 week of age onwards to avoid maternal rejection of the pups) and food intake (from weaning). 136 
Systolic blood pressure (SBP), biochemical markers (total, LDL and HDL cholesterol) and CRP, and 137 
colonies of the bone marrow mononuclear cells were measured up till 24 weeks. 138 
 139 
Study part II 140 
In this part of the study, 50% of the HF-fed females were given the water-soluble Pravastatin (Sigma 141 
UK; 5 mg/kg/day) in their drinking water. These females were fed the assigned diet and treated with 142 
statin through weaning to pregnancy and lactation. After birth, the pups were weighed and litter size 143 
was reduced to 8 female pups. From weaning (21 days postpartum), offsprings from the HF and HF+ S 144 
dams were fed the same HF diet, and were referred to as the HF/HF and HF+S/HF dietary groups, 145 
respectively. Offsprings from the dams fed on the same diet post-weaning were referred to as the C/C 146 
group (Figure 1). Colonies of bone marrow-derived mononuclear cells were measured up until 24 147 
weeks. 148 
 149 
Tail cuff plethysmography 150 
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Systolic arterial pressure was measured by tail cuff plethysmography, as we described previously (29-151 
31). In brief, measurements were conducted in a heated room (34 °C) to get optimal blood pressure 152 
(BP) readings and were conducted at the same time during the day (afternoon). All of the animals were 153 
accustomed to the procedure for 7 days before each BP measurement session. At least 5 readings were 154 
taken from each animal per session with the highest and lowest readings discarded, and the remaining 155 
readings were averaged to get a single session value. We took the average BP values from 8 female 156 
offspring picked randomly from each of the 8 litters in each treatment group. Tail cuff method has 157 
served a valuable role in experimental hypertension research for many years and continues to be useful 158 
in study designs. We specifically used this method as it shares some advantages: (1) It is non-invasive 159 
and does not require general anaesthesia and surgery; (2) it can be used to obtain repeated 160 
measurements of SBP in conscious animals during studies of short or long duration; (3) It requires less 161 
expensive equipment than the alternative of radio-telemetry and is also less expensive to operate; and 162 
(4) it can be used to screen for systolic hypertension or substantial differences in SBP among large 163 
numbers of animals.   164 
 165 
Serum lipid profile measurements 166 
A blood sample was drawn by direct heart puncture after anesthetizing the animal with isofluorane and 167 
cervical dislocation. We sampled 8 female offspring picked randomly from each of the 8 litters in each 168 
treatment group. Total cholesterol, low-density lipoprotein (LDL) cholesterol and high density 169 
lipoprotein (HDL) cholesterol in the serum were measured with commercially available kits (Vitros 170 
Products) using enzymatic methods and reflectance spectrophotometry, as reported previously (29, 30). 171 
 172 
C-reactive protein (CRP) measurement 173 
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CRP was measured using a quantitative sensitive double-antibody sandwich enzyme-linked 174 
immunosorbent assay.  In this assay anti-CRP antibodies were coated to the surfaces of polystyrene 175 
microtiter wells. Plasma samples were added and incubated at 37 0C for 2 hours. After washing, to 176 
remove unbound proteins, anti-mouse CRP antibodies conjugated with horseradish peroxidase (HRP) 177 
were added. These enzyme-labelled antibodies form complexes with the previously plate-bound CRPs. 178 
After another washing step, the enzyme bound to the immunosorbent is assayed by the addition of a 179 
chromogenic substrate, 3,3’,5,5’-tetramethylbenzidine (TMB). The quantity of bound enzyme is 180 
proportional to the concentration of CRPs; thus, the absorbance, at 450 nm, is a measure of the 181 
concentration of CRPs in the test sample. The quantity of CRPs in the test sample was interpolated 182 
from the standard curve constructed from the standards, and corrected for sample dilution. 183 
 184 
Culture and staining  185 
Bone marrow from mice femurs were collected into tubes containing buffered saline (HANKS). 6 ml of 186 
diluted sample was layered over 3 ml Lymphoprep in a 15 ml centrifuge tube, centrifuged at 800 x g 187 
for 20 minutes at room temperature (approximately 20 ºC). Samples were spun in wells (Lab-Tek ™ II 188 
Chamber slide) containing 400 μL of Dulbecco’s modified Eagle medium (D-MEM/F-12). Once the 189 
centrifugation process was over, mononuclear cells from the interphase were transferred to 15 ml 190 
centrifuge tubes containing 10 ml phosphate buffered saline (PBS). The cell suspensions were 191 
centrifuged at least twice at 200 g for 5 min at room temperature (25 ºC) with brakes. The supernatants 192 
were removed and cells suspended in 200 µL PBS were plated into incubation slides and incubated for 193 
an hour at 37 ºC. After an hour, 200 µl of fresh D-MEM/F-12 media were added to each well of the 194 
slide and incubated for 48-96 hours. Viable cells were counted using Trypan blue staining (0.4% stock 195 
solution).  196 
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 197 
Detection of bone marrow EPCs with double-staining 198 
To each well containing 500 µl of cell suspensions, 25 µl of acetylated low density lipoprotein labelled 199 
with 1,1’-deoctadecyl-3,3,3’,3’-tetramethyllindo-carbocyanine perchlorate (Dil-Ac-LDL) stain was 200 
added and gently mixed once or twice and then the slide was incubated for 4 h at 37 ºC. After 4 h, the 201 
chamber slides were examined under the microscope with green filter for red staining (RITC). Following 202 
this step, the media from the wells were removed, and the cells were gently washed with PBS three 203 
times. Cells were then fixed in 500 µl/well of Paraformaldehyde (3.7% in PBS) on ice for 30 min. After 204 
the fixation stage, cells were incubated in 200 µL Ulex Europaeus lectin (UEA) solution made up of 10 205 
µl of UEA suspended in 990 µl of PBS (stock 1mg/ml) for 1 h at 37 ºC without CO2 and in the dark. The 206 
cells were then gently washed up to 3 times every 5 min in the dark using PBS. The slides were mounted 207 
using citifluor and were examined under a microscope using UV purple lens and an inverted coverslip 208 
containing a drop of fluid composed of 90% glycerol and 10% PBS.  209 
 210 
Phase contrast and fluorescence imaging 211 
Phase contrast and fluorescence images were collected using a Zeiss Axiovert 2 inverted microscope 212 
with a 5x CP-ACHROMAT/0.12 NA objective. Images were acquired using a SPOT RT colour camera 213 
(Diagnostic Instruments, Sterling Heights, MI) with the manufacturer's software. Composite images were 214 
assembled in Adobe Photoshop version 8.0.  215 
 216 
Data analysis 217 
The biochemical and biophysical parameters in the dams were analysed using one-way analysis of 218 
variance followed by the Tukey–Kramer comparisons test. All data are expressed as mean values with 219 
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their standard errors. P-values < 0.05 were considered to be statistically significant. All statistical 220 
analyses were performed using SPSS 14.0 (SPSS, Inc., Chicago, IL, USA). 221 
 222 
RESULTS 223 
The effect of prenatal and postnatal high-fat diet consumption on risk factors for cardiovascular 224 
disease in female offsprings 225 
 226 
Females offsprings with a dietary profile history of C/HF, HF/C and HF/HF were heavier (Figure 2A), 227 
had significantly higher systolic blood pressure (Figure 2B), with increased serum levels of LDL-228 
cholesterol (Figure 2C) and CRP (Figure 2D) than C/C offspring at 24 weeks. Total cholesterol levels 229 
were significantly increased in female offsprings on a diet history of HF/C and HF/HF compared with 230 
control C/C at 24 weeks. However, the differences in total cholesterol were not observed in female 231 
offsprings on a diet history of C/HF as compared with the control C/C diet group (Figure 2E). Short-232 
term statin therapy (second half of pregnancy and lactation) in mothers on prenatal HF diet did not 233 
affect systolic blood pressure in female offsprings (Figure 2B). In contrast, short-term pravastatin 234 
therapy in mothers given HF diet during pregnancy significantly reduced bodyweight and LDL-235 
cholesterol in female offsprings whether or not they were on the postnatal HF diet. In addition, 236 
pravastatin therapy reduced the levels of CRP to negligible in HF+S/C and HF+S/HF female 237 
offsprings. 238 
 239 
The effect of prenatal and postnatal HF diet consumption on bone marrow mononuclear EPCs in 240 
female offsprings 241 
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HF diet (prenatal or postnatal) significantly reduced percentage of positively stained bone marrow 242 
mononuclear cells, decreased the number of double stained colonies and inhibited the expression of 243 
acetylated low-density lipoprotein (Figure 3). Pravastatin treatment to these hypercholesterolemic dams 244 
significantly improved and increased the number of bone marrow EPC observed in the culture. 245 
Representative photomicrographs of bone marrow EPC colonies stained for endothelial markers Dil-246 
Ac-LDL (red) and lectin (green) are shown in figure 4. 247 
 248 
The relationship of hypercholesterolemia with bone marrow mononuclear EPC numbers 249 
 250 
Bone marrow mononuclear EPC numbers were inversely correlated to the total cholesterol values 251 
(Figure 5A) and LDL-cholesterol (Figure 5B) levels. In contrast, there was no strong correlation 252 
between the number of bone marrow mononuclear EPCs and HDL-cholesterol levels (r = 0.237, P > 253 
0.05). Total cholesterol (standard coefficient = −0.530, P < 0.001) and LDL cholesterol (standard 254 
coefficient = −0.417, P < 0.01) were both independently correlated with lower bone marrow EPC 255 
numbers. 256 
 257 
The effect of pravastatin treatment to pregnant dams fed a HF diet on bone marrow EPC 258 
number and colonies in female offsprings after a post-weaning HF diet 259 
 260 
As summarised in figure 6, for female offsprings HF/HF dietary history significantly inhibits bone 261 
marrow mononuclear EPC numbers and colonies, thereby affecting key components of angiogenesis 262 
and endothelial repair. In contrast, in dams fed on a HF diet, pravastatin treatment started in early life 263 
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and continued right through pregnancy appears to protect their female offsprings from HF diet-induced 264 
depletion of bone marrow mononuclear EPC numbers and colonies (Figure 6). 265 
 266 
DISCUSSION   267 
The present study investigates whether long-term maternal HF diet has an impact on the expression of 268 
bone marrow endothelial progenitor cells (double stained endothelial progenitors, EPCs) in their female 269 
offsprings even if they were fed a HF or C diet right through their lives, i.e. to study the role of prenatal 270 
and postnatal diet on EPCs. To understand potential underlying mechanisms, we studied both the short-271 
term (second half of pregnancy and lactation) and long-term effects (soon after weaning through to 272 
pregnancy and lactation) on bone marrow mononuclear EPC numbers and colonies in female offsprings 273 
from mothers on a high-fat diet treated with or without pravastatin. 274 
 275 
The results demonstrate that: (1) bone marrow EPC numbers and expression in female offspring 276 
exposed prenatally or postnatally (C/HF, HF/HF and HF/C) to the HF diet are significantly decreased; 277 
(2) treating dams with Pravastatin (in both study protocols) proves beneficial for improving bone 278 
marrow EPC colony forming units in their offspring irrespective of their postnatal diet; (3) number of 279 
bone marrow EPC is inversely correlated with total cholesterol and LDL-cholesterol levels (4) and 280 
LDL-cholesterol is a predictor of bone marrow EPC expression. To date, it has been suggested that 281 
statins mobilize EPCs independent of their cholesterol lowering effects. Indeed, findings from our work 282 
also support the hypothesis that there is a relationship between statins and improvement in bone 283 
marrow EPC numbers in female offsprings with a history of prenatal and postnatal HF+S/HF diet. The 284 
effect may be related to the abrogation of CRP-induced inflammation and improvement in the 285 
cholesterol profile. Although previous studies have reported the role of statin in improving 286 
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angiogenesis (21, 22), this had not been observed in studies before in the context of the DOHaD 287 
phenomenon.  288 
 289 
Studies and laboratory evidence have identified that EPCs participate in postnatal neovascularization 290 
and re-endothelialization (6-37). In, this study we have observed that hypercholesterolemia can 291 
decrease bone marrow EPC number and activity. Given the well-established role of EPCs in 292 
neovascularisation and re-endothelization, our findings may have identified a possible 293 
pathophysiological mechanism related to hypercholesterolemia, i.e., hypercholesterolemia not only 294 
impairs endothelial cells directly, but also affects bone marrow EPC numbers and function at the same 295 
time. Thus hypercholesterolemia may influence the endothelial repair process and alter the balance 296 
between the magnitude of injury and the capacity for repair, which leads to endothelial dysfunction, 297 
and promote the early progression of coronary artery disease (CAD) in adult offspring.  298 
 299 
On the other hand statins have been developed as lipid-lowering drugs, and are well established to 300 
reduce morbidity and mortality from CAD (38). Besides lipid lowering, primary and secondary 301 
prevention trials and laboratory investigations established that statins possess favourable effects 302 
independent of cholesterol reduction (4, 39). In particular, statins have recently been reported to 303 
promote EPC proliferation, migration and cell survival in vitro (39-41). A recently performed clinical 304 
study demonstrated an increase in EPC number with enhanced migratory activity by statin treatment in 305 
patients with stable CAD (40). Results of this work, together with the findings of other investigators 306 
suggested a possible mechanism of action for statins in the augmentation and promotion of EPC 307 
functional activity. 308 
 309 
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More recently, two groups have documented in animals and human subjects that EPCs contribute up to 310 
25% of endothelial cells in newly formed vessels (41-43). Thus, increasing the number of circulating 311 
EPCs by transplantation of hematopoietic stem cells or by injection of in vitro-differentiated EPCs has 312 
been shown to improve neovascularization of ischemic hind-limbs, accelerate blood flow in diabetic 313 
mice (6) and improve cardiac function (36). More importantly, reports suggest that patients with CAD 314 
reveal reduced levels and functional impairment of EPCs which correlates with risk factors of CAD 315 
(33, 34). One may wonder what would be the mechanisms. It might be due to increased apoptosis of 316 
premature progenitor cells or oxidised LDL known to induce apoptotic cell death. It may well be 317 
hypercholesterolemia that could interfere with the signalling pathways regulating EPC differentiation 318 
or mobilization. The mechanistic effects of statins on EPC in such settings may be related to their 319 
impact on increased regional blood perfusion most probably mediated by increased production of 320 
endothelial NO (44, 45), or induced EPC differentiation by reducing CRP-mediated inflammation (40-321 
42). Further work is therefore needed to elucidate the underlying mechanisms that may explain why 322 
and how high-fat diets have a deleterious effects and cause functional impairment of bone marrow 323 
EPCs in mothers and their female offsprings. 324 
 325 
CONCLUSION 326 
In conclusion, our work has demonstrated that maternal hypercholesterolemia is associated with 327 
reduction in bone marrow EPC numbers and differentiation. It has been suggested that statins mobilize 328 
EPCs independent of their cholesterol lowering effects. However, evidence from our work suggests 329 
that there is a possible relationship between statins and improvement in bone marrow EPC numbers 330 
which may be related to the combination of the abrogation of CRP-induced inflammation and 331 
improvement in the cholesterol profile. This may suggest a potential important direction for future 332 
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investigations in the developmental origins of CVD. Such studies will expand our understanding of the 333 
underlying pathophysiology. 334 
 335 
There are some limitations of our work. It is difficult to deduce from our findings that the decrease in the 336 
number of bone marrow EPCs in HF/HF is directly influenced by the maternal diet and thus contribute to 337 
the defect in postnatal vascular response, i.e. bone marrow EPCs mediated mobilization and endothelial 338 
function. There seems to be a discrepancy between the effects statin treatment has in HF/HF regarding 339 
blood pressure on the one hand (no effect), and lipids and bone marrow EPC numbers on the other. 340 
Whether statins alter endothelial cell phenotype in these animals is not clear. This is an important 341 
consideration since mice do not generally develop overt vascular pathology (e.g. atherosclerosis), even 342 
with severe obesity models like a high-fat diet. This might point at a different mode of action for blood 343 
pressure regulation that deserves further investigations and this might have relevance to understanding of 344 
the underlying pathophysiology. Indeed, it is not known whether different target organs are affected 345 
(liver, kidney, and vasculature), a question that requires further investigations. In this study, we 346 
harvested mononuclear cells from the bone-marrow and not from the peripheral blood. We acknowledge 347 
that there are a host of other mechanisms that regulate the entry of bone marrow EPCs into the peripheral 348 
blood circulation and therefore levels in bone marrow aspirates may not truly reflect this. Preferably, 349 
measurement of levels of circulating EPCs may better provide information about the ability of these cells 350 
to translocate to areas within the circulation where vascular repair is needed. In addition, it would have 351 
been advantageous to conduct fluorescence-activated cell sorting (FACS) for cultured mononuclear cells 352 
to evaluate whether these cells progressed to an EPC-like phenotype rather than relying on the double 353 
staining alone to identify them.  Our work was limited by shortage of funding and other research 354 
resources, and hence we mainly focused on the effect of the high-fat diet and treatment with statins on 355 
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endothelial progenitor cells. We acknowledge that there were large quantities of other types of bone 356 
marrow cells such as CD14 that could have been investigated more thoroughly. 357 
 358 
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FIGURE LEGENDS: 
Figure 1: Flow diagram of the experimental protocol.  
 
Figure 2: Comparison of body weight gain (A), blood pressure (B), LDL (C), CRP (D) and cholesterol 
(E) levels in female offspring (at 24 weeks of age) from control-fed mothers that were then fed a chow 
diet (C/C) or high-fat diet (C/HF) and from high-fat-fed mothers that were then fed a high-fat diet 
(HF/HF) or a chow diet (HF/C) and from high-fat-statin fed mothers that were then fed a high-fat diet 
(HF+S/HF) or a chow diet (HF+S/C). Values are means (n = 8 per group), with standard errors 
represented by vertical bars, a, b, c and d. Mean values with dissimilar lettering indicated significant 
differences (P < 0·05; Tukey–Kramer comparisons test). Statin treatment in hypercholesterolemic 
mothers during late pregnancy and lactation has beneficial effects on the body weight, blood pressure, 
LDL levels, CRP levels and cholesterol profile in their offspring. 
 
Figure 3: Comparison of positively stained bone marrow mononuclear cells described as bone marrow 
endothelial progenitor cells (EPCs) (A) and number of double stained colonies (per 106 cells) (B) in 
female offspring (at 24 weeks of age) from control-fed mothers that were then fed a chow diet (C/C) or 
high-fat diet (C/HF) and from high-fat-fed mothers that were then fed a high-fat diet (HF/HF) or a 
chow diet (HF/C) and from high-fat-statin fed mothers that were then fed a high-fat diet (HF+S/HF) or 
a chow diet (HF+S/C). Values are means (n = 8 per group), with standard errors represented by vertical 
bars. a, b, c and d. Mean values with dissimilar lettering indicated significant differences (P < 0·05; 
Tukey–Kramer comparisons test). Pravastatin treatment in hypercholesterolemic mothers during late 
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pregnancy and lactation has beneficial effects on the positively stained bone marrow EPCs and the 
number of double stained colonies in offsprings from mothers on high fat-high cholesterol (HF) diet.   
 
Figure 4: Expression of endothelial markers on bone marrow mononuclear EPCs. Representative 
photomicrographs of EPC colonies stained for endothelial markers Dil-Ac-LDL (red) and lectin 
(green). EPC colonies demonstrate reduced staining in HF/HF vs C/C. Statin treatment to HF-fed dams 
abolished these effects in their offspring. Measurements were made at 24 weeks of age 
 
Figure 5: Correlation between the number of bone marrow EPCs from HF/HF offspring with 
hypercholesterolemia and total cholesterol (A) and LDL-cholesterol (B) levels. (Age = 24 weeks) 
 
Figure 6:  The effect of long-term statin treatment in hypercholesterolemic mothers on bone marrow 
EPCs: (A) number of stained bone marrow EPC colonies (B) percentage of mononuclear cells that are 
Fluorescein Isothiocyanate (FITC) labelled. Weaned offsprings were then fed either HF or C diets 
through adulthood, thus generating the dam/offspring dietary groups of HF/HF, HF-S/HF and C/C (n = 
8 per group; Age = 24 weeks). 
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